Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Tmem43em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Tmem43em1/Cya

Common Name
Tmem43-KO
Product ID
S-KO-14294
Backgroud
C57BL/6JCya
Strain ID
KOCMP-74122-Tmem43-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Tmem43-KO Mouse (Catalog S-KO-14294) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Tmem43-KO
Strain ID
KOCMP-74122-Tmem43-B6J-VA
Gene Name
Tmem43
Product ID
S-KO-14294
Gene Alias
LUMA, 1200015A22Rik
Background
C57BL/6JCya
Gene Full Name
transmembrane protein 43
Modification
Conventional knockout
NCBI ID
74122 (Mouse)
Phenotype
MGI:1921372
Chromosome
Chr 6 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000032183
NCBI Transcript ID
NM_028766
Target Region
Exon 2~12
Size of Effective Region
~10.5 kb
Overview of Gene Research
TMEM43, also known as LUMA, is a transmembrane protein encoded by a highly conserved gene, ubiquitously expressed from bacteria to humans. It is involved in multiple biological processes and is associated with pathways related to cardiac function, metabolism, and cell growth. Genetic models, such as knockout mouse models, have been crucial in understanding its functions [2,3,6].

In mouse models, TMEM43 knockdown in hearts deteriorated lipopolysaccharide (LPS)-induced cardiac injury and dysfunction, while overexpression alleviated these effects by inhibiting ferroptosis, a form of cell death. Mechanistically, TMEM43 regulated the expression of proteins like P53, ferritin, Gpx4, and SLC7A11 [1]. Mutant mouse models with the TMEM43-S358L mutation showed classic pathologies of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), including structural abnormalities, cardiac fibrofatty changes, and hyper-activated NF-κB-TGFβ signal cascade [4,5]. In zebrafish, overexpression of wild-type and mutant TMEM43 led to cardiac morphological and ultrastructural changes, along with dysregulated gene expression [7].

In conclusion, TMEM43 plays essential roles in protecting against sepsis-induced cardiac injury via inhibiting ferroptosis and is involved in the pathogenesis of ARVD/C. The use of KO/CKO mouse models and other genetic models has significantly contributed to understanding its functions in these disease-related processes, which may provide potential therapeutic strategies for related diseases in the future [1,4,5].

References:
1. Chen, Zhen, Cao, Zhe, Gui, Feng, Ai, Fen, Zhang, Jun. 2022. TMEM43 Protects against Sepsis-Induced Cardiac Injury via Inhibiting Ferroptosis in Mice. In Cells, 11, . doi:10.3390/cells11192992. https://pubmed.ncbi.nlm.nih.gov/36230956/
2. Heller, Scott A, Shih, Renata, Kalra, Raghav, Kang, Peter B. 2019. Emery-Dreifuss muscular dystrophy. In Muscle & nerve, 61, 436-448. doi:10.1002/mus.26782. https://pubmed.ncbi.nlm.nih.gov/31840275/
3. Zhang, Nannan, Wang, Feiran, Yang, Xiaobing, Feitelson, Mark A, Chen, Zhong. 2024. TMEM43 promotes the development of hepatocellular carcinoma by activating VDAC1 through USP7 deubiquitination. In Translational gastroenterology and hepatology, 9, 9. doi:10.21037/tgh-23-108. https://pubmed.ncbi.nlm.nih.gov/38317750/
4. Zheng, Guoxing, Jiang, Changying, Li, Yulin, Du, Jie, Lin, Xin. 2018. TMEM43-S358L mutation enhances NF-κB-TGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy. In Protein & cell, 10, 104-119. doi:10.1007/s13238-018-0563-2. https://pubmed.ncbi.nlm.nih.gov/29980933/
5. Orgil, Buyan-Ochir, Munkhsaikhan, Undral, Pierre, Joseph F, Towbin, Jeffrey A, Purevjav, Enkhsaikhan. 2023. The TMEM43 S358L mutation affects cardiac, small intestine, and metabolic homeostasis in a knock-in mouse model. In American journal of physiology. Heart and circulatory physiology, 324, H866-H880. doi:10.1152/ajpheart.00712.2022. https://pubmed.ncbi.nlm.nih.gov/37083466/
6. Ratnavadivel, Sandra, Dammeier, Joline, Gaertner, Anna, Paululat, Achim, Milting, Hendrik. 2024. Generation of a TMEM43 knockout human induced pluripotent stem cell line (HDZi003-A-1) using CRISPR/Cas9. In Stem cell research, 76, 103354. doi:10.1016/j.scr.2024.103354. https://pubmed.ncbi.nlm.nih.gov/38430734/
7. Zink, Miriam, Seewald, Anne, Rohrbach, Mareike, Childs, Sarah J, Gerull, Brenda. 2022. Altered Expression of TMEM43 Causes Abnormal Cardiac Structure and Function in Zebrafish. In International journal of molecular sciences, 23, . doi:10.3390/ijms23179530. https://pubmed.ncbi.nlm.nih.gov/36076925/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research